Key points are not available for this paper at this time.
The aim of this study was to describe the effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid (SUA) in patients with type 2 diabetes mellitus (T2DM). PubMed, CENTRAL, EMBASE and ClinicalTrials.gov were searched for randomized controlled trials of SGLT2 inhibitors in patients with T2DM up to May 20, 2017. A total of 62 studies, comprising 34 941 patients, were included. Any of the SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, tofogliflozin, luseogliflozin or ipragliflozin) significantly decreased SUA levels compared with control (total weighted mean difference WMD −37.73 μmol/L, 95% CI −40.51, −34.95). Treatment with empagliflozin resulted in a superior reduction in SUA (WMD −45.83 μmol/L, 95% CI −53.03, −38.63). The effect persisted during long‐term treatment. Dapagliflozin decreased SUA in a dose‐dependent manner (from 5 to 50 mg, P = .014). In subgroup analyses, greater reductions could be observed during the course of early diabetes and the SUA‐lowering effect was abolished in patients with chronic kidney disease (estimated glomerular filtration rate <60 mL/min per 1.73 m 2 ). The effect of SGLT2 inhibitors on SUA reduction suggests that this class of drugs might be beneficial for diabetic patients with hyperuricaemia.
Zhao et al. (Mon,) studied this question.